PMID- 22810739
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20161018
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 112
IP  - 4
DP  - 2012
TI  - [The prognostic significance of brain-derived neurotrophic factor (BDNF) for 
      phobic anxiety disorders, vegetative and cognitive impairments during 
      conservative treatment including adaptol of some functional and organic diseases 
      of nervous system].
PG  - 37-41
AB  - We have studied the efficacy of adaptol in the treatment of 45 patients with 
      somatoform dysfunction of the autonomic nervous system and 30 patients with 
      closed head injury. The condition of patients during the treatment was evaluated 
      with clinical and neuropsychological scales. The serum level of BDNF before and 
      after the treatment has been studied as well. Adaptol has been shown to enhance 
      the production of BDNF, reduce significantly the intensity of anxiety, autonomic 
      disorders and improve intellectual processes. The dose-dependent effect of the 
      drug has been demonstrated. In conclusion, adaptol can be recommended for 
      treatment of diseases that demand stimulation of neuroplasticity in the CNS.
FAU - Zhivolupov, S A
AU  - Zhivolupov SA
FAU - Samartsev, I N
AU  - Samartsev IN
FAU - Marchenko, A A
AU  - Marchenko AA
FAU - Puliatkina, O V
AU  - Puliatkina OV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Biureas)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 10095-06-4 (mebikar)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Anxiety Agents/administration & dosage/*therapeutic use
MH  - Anxiety Disorders/blood/*drug therapy
MH  - Autonomic Nervous System Diseases/blood/*drug therapy
MH  - Biureas/administration & dosage/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognition Disorders/blood/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Middle Aged
MH  - Phobic Disorders/blood/*drug therapy
MH  - Prognosis
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/07/20 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/07/20 06:00
PHST- 2012/07/20 06:00 [entrez]
PHST- 2012/07/20 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(4):37-41.